Key result
Intravenous tirofiban improved 90-day functional recovery in stroke patients with large artery occlusion and NIHSS > 13 (adjusted OR 4.671), but showed no benefit in cardioembolic stroke.
Why the study?
Experience with intravenous tirofiban regarding efficacy and safety in ischemic stroke has yielded conflicting results, and precise candidate selection for targeted treatment remains undefined.
Does intravenous tirofiban improve favorable functional recovery at 90 days in acute ischemic stroke patients achieving optimal large-vessel recanalization?
Population
Patients with acute ischemic stroke and optimal large-vessel recanalization in the RESCUE BT trial
Comparison
Intravenous tirofiban before endovascular treatment vs placebo
Design
Post hoc analysis of the RESCUE BT trial
Follow-up
90 days
Authors
Loading...
May support adjunctive tirofiban with EVT to improve outcomes and reduce mortality in AIS without excess sICH; leaves open confirmation by large RCTs.
Does intravenous tirofiban improve favorable functional recovery at 90 days in acute ischemic stroke patients achieving optimal large-vessel recanalization?
Odds Ratio: 4.671
Intravenous tirofiban before endovascular treatment may improve functional outcomes in acute ischemic stroke patients with large artery atherosclerosis and high NIHSS scores, but caution is warranted in cardioembolic stroke.
Arboix et al. (2025) conducted an editorial in Acute ischemic stroke. Intravenous tirofiban vs. Placebo was evaluated on Favorable functional recovery at 90 days (mRS ≤ 2) (adjusted OR 4.671). Intravenous tirofiban improved 90-day functional recovery in stroke patients with large artery occlusion and NIHSS > 13 (adjusted OR 4.671), but showed no benefit in cardioembolic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: